Skip to Content
Merck

Pangenomic Classification of Pituitary Neuroendocrine Tumors.

Cancer cell (2019-12-31)
Mario Neou, Chiara Villa, Roberta Armignacco, Anne Jouinot, Marie-Laure Raffin-Sanson, Amandine Septier, Franck Letourneur, Ségolène Diry, Marc Diedisheim, Brigitte Izac, Cassandra Gaspar, Karine Perlemoine, Victoria Verjus, Michèle Bernier, Anne Boulin, Jean-François Emile, Xavier Bertagna, Florence Jaffrezic, Denis Laloe, Bertrand Baussart, Jérôme Bertherat, Stephan Gaillard, Guillaume Assié
ABSTRACT

Pituitary neuroendocrine tumors (PitNETs) are common, with five main histological subtypes: lactotroph, somatotroph, and thyrotroph (POU1F1/PIT1 lineage); corticotroph (TBX19/TPIT lineage); and gonadotroph (NR5A1/SF1 lineage). We report a comprehensive pangenomic classification of PitNETs. PitNETs from POU1F1/PIT1 lineage showed an epigenetic signature of diffuse DNA hypomethylation, with transposable elements expression and chromosomal instability (except for GNAS-mutated somatotrophs). In TPIT lineage, corticotrophs were divided into three classes: the USP8-mutated with overt secretion, the USP8-wild-type with increased invasiveness and increased epithelial-mesenchymal transition, and the large silent tumors with gonadotroph transdifferentiation. Unexpected expression of gonadotroph markers was also found in GNAS-wild-type somatotrophs (SF1 expression), challenging the current definition of SF1/gonadotroph lineage. This classification improves our understanding and affects the clinical stratification of patients with PitNETs.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-TBX19 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL6251, purified immunoglobulin, buffered aqueous glycerol solution